Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
REGN Regeneron Pharmaceuticals	$890.68 -1.7%	$950.58	$684.80 ▼ $998.33	$97.76B	0.11	490,876 shs	574,971 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
REGN Regeneron Pharmaceuticals	-0.09%	+0.59%	-5.68%	-4.46%	+14.81%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
REGN Regeneron Pharmaceuticals	3.9966 of 5 stars	2.4	4.0	0.0	2.3	2.7	2.5	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$977.77	9.78% Upside

Current Analyst Ratings

Latest REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2024	REGN Regeneron Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,020.00 ➝ $1,030.00
4/17/2024	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00
4/15/2024	REGN Regeneron Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$925.00
4/12/2024	REGN Regeneron Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$710.00 ➝ $720.00
4/9/2024	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$1,189.00
4/3/2024	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1,135.00
3/26/2024	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1,135.00
3/13/2024	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$1,104.00 ➝ $1,115.00
3/12/2024	REGN Regeneron Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$1,125.00
2/27/2024	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$1,096.00 ➝ $1,184.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
REGN Regeneron Pharmaceuticals	$13.12B	7.45	$42.47 per share	20.97	$236.63 per share	3.76

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
REGN Regeneron Pharmaceuticals	$3.95B	$34.75	25.63	22.07	2.61	30.14%	17.61%	13.76%	5/2/2024 (Confirmed)

Latest REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/2/2024	N/A	REGN Regeneron Pharmaceuticals	$8.07	N/A	-$8.07	N/A	N/A	N/A
2/2/2024	12/31/2023	REGN Regeneron Pharmaceuticals	$10.73	$11.86	+$1.13	$10.17	$3.29 billion	$3.43 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
REGN Regeneron Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
REGN Regeneron Pharmaceuticals	0.10	5.69	4.94

Ownership

Institutional Ownership

Company	Institutional Ownership
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
REGN Regeneron Pharmaceuticals	8.83%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
REGN Regeneron Pharmaceuticals	13,450	109.76 million	100.07 million	Optionable

REGN Headlines

Source	Headline
	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 25 at 5:15 PM
	Mammoth Bio inks Crispr-based collaboration with Regeneron thepharmaletter.com - April 25 at 3:13 PM
	EXEL vs. REGN: Which Stock Is the Better Value Option? zacks.com - April 25 at 12:45 PM
	Regeneron (REGN) Reports Next Week: What You Should Expect zacks.com - April 25 at 11:05 AM
	Regeneron signs Mammoth gene editing deal worth $100M upfront fiercebiotech.com - April 25 at 10:12 AM
	Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN) markets.businessinsider.com - April 25 at 10:12 AM
	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases markets.businessinsider.com - April 25 at 10:12 AM
	Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies msn.com - April 25 at 10:12 AM
	Jennifer Doudna co-founded Peninsula biotech lands CRISPR gene-editing pact with Regeneron bizjournals.com - April 25 at 10:12 AM
	UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study finance.yahoo.com - April 25 at 10:12 AM
	AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study reuters.com - April 25 at 8:48 AM
	Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth reuters.com - April 25 at 7:14 AM
	Regeneron Pharmaceuticals (REGN) Scheduled to Post Earnings on Thursday americanbankingnews.com - April 25 at 1:28 AM
	Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alaska Permanent Fund Corp marketbeat.com - April 24 at 5:16 PM
	Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,030.00 at TD Cowen marketbeat.com - April 24 at 1:57 PM
	Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO globenewswire.com - April 24 at 10:05 AM
	Cantor Fitzgerald Brokers Raise Earnings Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) americanbankingnews.com - April 24 at 2:24 AM
	New York State Common Retirement Fund Has $131.92 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) marketbeat.com - April 23 at 12:28 PM
	FY2024 EPS Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raised by Analyst marketbeat.com - April 23 at 6:14 AM
	Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Buys 17,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) marketbeat.com - April 22 at 11:39 PM
	Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) globenewswire.com - April 22 at 5:54 PM
	Shikiar Asset Management Inc. Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) marketbeat.com - April 21 at 5:00 PM
	Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up to $893.99 americanbankingnews.com - April 21 at 1:42 AM
	abrdn plc Buys 186,215 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) marketbeat.com - April 20 at 12:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Regeneron Pharmaceuticals

NASDAQ:REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial